DWN12088, A Prolyl-tRNA Synthetase Inhibitor, Alleviates Hepatic Injury in Nonalcoholic Steatohepatitis

다국어 초록 (Multilingual Abstract)

Background: Nonalcoholic steatohepatitis (NASH) is a liver disease caused by obesity that leads to hepatic lipoapoptosis, resulting in fibrosis and cirrhosis. However, the mechanism underlying NASH is largely unknown, and there is currently no effective therapeutic agent against it. DWN12088, an agent used for treating idiopathic pulmonary fibrosis, is a selective prolyl-tRNA synthetase (PRS) inhibitor that suppresses the synthesis of collagen. However, the mechanism underlying the hepatoprotective effect of DWN12088 is not clear. Therefore, we investigated the role of DWN12088 in NASH progression.Methods: Mice were fed a chow diet or methionine-choline deficient (MCD)-diet, which was administered with DWN12088 or saline by oral gavage for 6 weeks. The effects of DWN12088 on NASH were evaluated by pathophysiological examinations, such as real-time quantitative reverse transcription polymerase chain reaction, immunoblotting, biochemical analysis, and immunohistochemistry. Molecular and cellular mechanisms of hepatic injury were assessed by <i>in vitro</i> cell culture.Results: DWN12088 attenuated palmitic acid (PA)-induced lipid accumulation and lipoapoptosis by downregulating the Rho-kinase (ROCK)/AMP-activated protein kinase (AMPK)/sterol regulatory element-binding protein-1c (SREBP-1c) and protein kinase R-like endoplasmic reticulum kinase (PERK)/α subunit of eukaryotic initiation factor 2 (eIF2α)/activating transcription factor 4 (ATF4)/C/EBP-homologous protein (CHOP) signaling cascades. PA increased but DWN12088 inhibited the phosphorylation of nuclear factor-κB (NF-κB) p65 (Ser536, Ser276) and the expression of proinflammatory genes. Moreover, the DWN12088 inhibited transforming growth factor β (TGFβ)-induced pro-fibrotic gene expression by suppressing TGFβ receptor 1 (TGFβR1)/Smad2/3 and TGFβR1/glutamyl-prolyl-tRNA synthetase (EPRS)/signal transducer and activator of transcription 6 (STAT6) axis signaling. In the case of MCD-diet-induced NASH, DWN12088 reduced hepatic steatosis, inflammation, and lipoapoptosis and prevented the progression of fibrosis.Conclusion: Our findings provide new insights about DWN12088, namely that it plays an important role in the overall improvement of NASH. Hence, DWN12088 shows great potential to be developed as a new integrated therapeutic agent for NASH.

참고문헌 (Reference)

• 1 Luo Y, "The role of halofuginone in fibrosis : more to be explored?" 102 : 1333-1345, 2017
• 2 Kershenobich D, "The relationship between the free pool of proline and collagen content in human liver cirrhosis" 49 : 2246-2249, 1970
• 3 Clark JM, "The prevalence and etiology of elevated aminotransferase levels in the United States" 98 : 960-967, 2003
• 4 Kim JH, "The nonprovitamin A carotenoid, lutein, inhibits NF-kappaB-dependent gene expression through redox-based regulation of the phosphatidylinositol 3-kinase/PTEN/Akt and NF-kappaB-inducing kinase pathways : role of H(2)O(2)in NF-kappaB activation" 45 : 885-896, 2008
• 5 Ziegler S, "Target identification for small bioactive molecules : finding the needle in the haystack" 52 : 2744-2792, 2013
• 6 Fabregat I, "TGF-β signalling and liver disease" 283 : 2219-2232, 2016
• 7 Tang S, "Suppression of Rho-kinase 1 is responsible for insulin regulation of the AMPK/SREBP-1c pathway in skeletal muscle cells exposed to palmitate" 54 : 635-644, 2017
• 8 Cho H, "Signaling dynamics of palmitate-induced ER stress responses mediated by ATF4 in HepG2 cells" 7 : 9-, 2013
• 9 Wei Y, "Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cells" 291 : E275-E281, 2006
• 10 Wei Y, "Saturated fatty acid-mediated endoplasmic reticulum stress and apoptosis are augmented by trans-10, cis-12-conjugated linoleic acid in liver cells" 303 : 105-113, 2007
• 11 Ferre P, "SREBP-1c transcription factor and lipid homeostasis : clinical perspective" 68 : 72-82, 2007
• 12 Bi Y, "Role for sterol regulatory element binding protein-1c activation in mediating skeletal muscle insulin resistance via repression of rat insulin receptor substrate-1 transcription" 57 : 592-602, 2014
• 13 Lee DK, "REDD-1aggravates endotoxin-induced inflammation via atypical NF-κB activation" 32 : 4585-4599, 2018
• 14 Harding HP, "Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase" 397 : 271-274, 1999
• 15 Turgeman T, "Prevention of muscle fibrosis and improvement in muscle performance in the mdx mouse by halofuginone" 18 : 857-868, 2008
• 16 Williamson RM, "Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes : the Edinburgh Type 2 Diabetes Study" 34 : 1139-1144, 2011
• 17 Viatour P, "Phosphorylation of NF-kappaB and IkappaB proteins : implications in cancer and inflammation" 30 : 43-52, 2005
• 18 Zeng X, "Oleic acid ameliorates palmitic acid induced hepatocellular lipotoxicity by inhibition of ER stress and pyroptosis" 17 : 11-, 2020
• 19 Hazlehurst JM, "Non-alcoholic fatty liver disease and diabetes" 65 : 1096-1108, 2016
• 20 Takaki A, "Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis(NASH)" 14 : 20704-20728, 2013
• 21 Wu W, "Metformin attenuates palmitic acid-induced insulin resistance in L6 cells through the AMP-activated protein kinase/sterol regulatory elementbinding protein-1c pathway" 35 : 1734-1740, 2015
• 22 Unger RH, "Lipoapoptosis : its mechanism and its diseases" 1585 : 202-212, 2002
• 23 Halevy O, "Inhibition of collagen type I synthesis by skin fibroblasts of graft versus host disease and scleroderma patients : effect of halofuginone" 52 : 1057-1063, 1996
• 24 Commerford SR, "In vivo regulation of SREBP-1c in skeletal muscle : effects of nutritional status, glucose, insulin, and leptin" 287 : R218-R227, 2004
• 25 Feldstein AE, "Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis" 125 : 437-443, 2003
• 26 Neuschwander-Tetri BA, "Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis : the central role of nontriglyceride fatty acid metabolites" 52 : 774-788, 2010
• 27 McGaha TL, "Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts" 118 : 461-470, 2002
• 28 Pines M, "Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma" 9 : 417-425, 2003
• 29 Chen GQ, "Halofuginone inhibits colorectal cancer growth through suppression of Akt/mTORC1 signaling and glucose metabolism" 6 : 24148-24162, 2015
• 30 Nelson EF, "Halofuginone down-regulates Smad3 expression and inhibits the TGFbeta-induced expression of fibrotic markers in human corneal fibroblasts" 18 : 479-487, 2012
• 31 Keller TL, "Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase" 8 : 311-317, 2012
• 32 Pines M, "Halofuginone : the multifaceted molecule" 20 : 573-594, 2015
• 33 Song DG, "Glutamyl-prolyl-tRNA synthetase induces fibrotic extracellular matrix via both transcriptional and translational mechanisms" 33 : 4341-4354, 2019
• 34 Zimmet P, "Global and societal implications of the diabetes epidemic" 414 : 782-787, 2001
• 35 McCullough KD, "Gadd153 sensitizes cells to endoplasmic reticulum stress by down-regulating Bcl2 and perturbing the cellular redox state" 21 : 1249-1259, 2001
• 36 Borradaile NM, "Disruption of endoplasmic reticulum structure and integrity in lipotoxic cell death" 47 : 2726-2737, 2006
• 37 ClinicalTrials.gov, "Clinical trial to evaluate the safety and efficacy of DWN12088 in patients with IPF"
• 38 Luedde T, "Cell death and cell death responses in liver disease : mechanisms and clinical relevance" 147 : 765-783, 2014
• 39 Kang YB, "Bioactive molecules : current trends in discovery, synthesis, delivery and testing" 7 (7): S32-S46, 2013
• 40 Kim Y, "Aminoacyl-tRNA synthetase inhibition activates a pathway that branches from the canonical amino acid response in mammalian cells" 117 : 8900-8911, 2020
• 41 Kilberg MS, "ATF4-dependent transcription mediates signaling of amino acid limitation" 20 : 436-443, 2009
• 42 Salminen A, "AMP-activated protein kinase inhibits NF-κB signaling and inflammation : impact on healthspan and lifespan" 89 : 667-676, 2011
• 43 Lee CH, "A first-in-class PRS inhibitor, DWN12088, as a novel therapeutic agent for idiopathic pulmonary fibrosis" 202 : A2786-, 2020